GUILFORD, Conn. & ROCKVILLE, Md.--(BUSINESS WIRE)--Dec 19, 2024--
Drug Farm, a clinical-stage biopharmaceutical company developing innovative treatments targeting innate immunity, announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to develop a precision targeted drug, DF-003 for the treatment of ROSAH (retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis and headache) syndrome. DF-003 is a first-in-class highly selective ALPK1 inhibitor with nanomolar potency that can cross the blood-retina barrier and has demonstrated preclinical efficacy in a transgenic ROSAH mouse model. DF-003 has completed Phase 1 evaluation in healthy subjects and will be evaluated in patients with ROSAH syndrome. Under the terms of the agreement, Drug Farm will sponsor and partner with NIAID on a clinical trial ( NCT06395285 ) to assess the safety, pharmacokinetics and efficacy of DF-003 in people with ROSAH. "NIAID is a leader in ROSAH syndrome research and we are excited about partnering with NIAID as a first step towards developing a precision targeted drug that has potential for providing therapeutic benefit to people with ROSAH syndrome," said Dr. Henri Lichenstein, Chief Executive Officer at Drug Farm.
kAmp3@FE #~$pw $J?5C@>6k^Am kAm#~$pw WC6E:?2= 5JDEC@A9J[ @AE:4 ?6CG6 656>2[ DA=6?@>682=J[ 2?9:5C@D:D 2?5 96252496X DJ?5C@>6 :D 2 C2C6[ 2FE@D@>2= 5@>:?2?E 2FE@:?7=2>>2E@CJ 86?6E:4 5:D62D6 ?2>65 244@C5:?8 E@ E96 492C24E6C:DE:4 DJ>AE@>D 6I9:3:E65 3J 27764E65 A2E:6?ED W'[ aX] s:D62D6\42FD:?8 >FE2E:@?D :? p{!z' =625 E@ #~$pw $J?5C@>6] %96 >@DE 4@>>@? AC6D6?E:?8 DJ>AE@> :D 2 AC@8C6DD:G6 564=:?6 :? G:DF2= 24F:EJ E92E EJA:42==J 368:?D 367@C6 a_ J62CD @7 286[ H:E9 @A9E92=>@=@8:4 6I2>:?2E:@? @7E6? C6G62=:?8 @AE:4 5:D4 6=6G2E:@?[ FG6:E:D[ 2?5 C6E:?2= ?6CG6 5686?6C2E:@? Wa[ bX] |@DE #~$pw A2E:6?ED 2=D@ 6I9:3:E :?7=2>>2E@CJ 762EFC6D DF49 2D ?@?\:?764E:@FD =@H\8C256 76G6CD[ 2CE9C2=8:2[ 96252496D[ 2?5 A6CD:DE6?E=J 6=6G2E65 =6G6=D @7 :?7=2>>2E@CJ 4JE@<:?6D :?4=F5:?8 EF>@C ?64C@D:D 724E@C\α W%}uαX[ :?E6C=6F<:?\e Wx{\eX[ 2?5 x{\'β WbX]k^AmkAm'] %2?EC2G29: $z[ 6E 2=] p? :?96C:E65 5:D@C56C H:E9 DA=6?@>682=J[ 4JE@A6?:2D[ 2?5 G:D:@? =@DD] p> y |65 v6?6E p] a_'aj'dgWbXicfd\g']k^AmkAma] (:==:2>D {q[ 6E 2=] p{!z' >:DD6?D6 A2E9@86?:4 G2C:2?E :? 7:G6 72>:=:6D =625D E@ #~$pw DJ?5C@>6[ 2? @4F=2C >F=E:DJDE6> 2FE@D@>2= 5@>:?2?E 5:D@C56C] v6?6E |65] a_'hja'WhXia'_b\'d]k^AmkAmb] z@KJ4<: r%[ 6E 2=] v2:?\@7\7F?4E:@? >FE2E:@?D :? p{!z' 42FD6 2? }u\κq\>65:2E65 2FE@:?7=2>>2E@CJ 5:D62D6i 7F?4E:@?2= 2DD6DD>6?E[ 4=:?:42= A96?@EJA:?8 2?5 5:D62D6 4@FCD6 @7 A2E:6?ED H:E9 #~$pw DJ?5C@>6] p?? #96F> s:D] a_aajg'W'_Xi'cdb\ec]k^AmkAmp3@FE su\__bk^AmkAmsu\__b :D 2 7:CDE\:?\4=2DD 5CF8 56G6=@A65 3J sCF8 u2C> E92E :?9:3:ED E96 24E:G:EJ @7 p{!z' 2?5 G2C:2?ED @7 p{!z' E92E 42FD6 #~$pw DJ?5C@>6] su\__b 92D 4@>A=6E65 2 !92D6 ' 4=:?:42= EC:2= W}r%_dhhfec'X :? ?@C>2= 962=E9J G@=F?E66CD]k^AmkAmp3@FE sCF8 u2C>k^AmkAmsCF8 u2C> :D 2 AC:G2E6 3:@E649?@=@8J r@>A2?J 56G6=@A:?8 :??@G2E:G6 EC62E>6?ED E2C86E:?8 :??2E6 :>>F?:EJ 7@C 96A2E:E:D q[ 962CE 2?5 <:5?6J 5:D62D6D[ 2?5 #~$pw WC6E:?2= 5JDEC@A9J[ @AE:4 ?6CG6 656>2[ DA=6?@>682=J[ 2?9:5C@D:D 2?5 96252496X DJ?5C@>6] sCF8 u2C>VD F?:BF6 xsx?':G@ A=2E7@C> 4@>3:?6D 3C62<E9C@F89 E649?@=@8:6D :? 86?6E:4D 2?5 px E@ 5:D4@G6C ?6H EC62E>6?ED] xsx?':G@ E649?@=@8J 2==@HD E96 5:C64E 2DD6DD>6?E @7 86?6 E2C86ED :? =:G:?8 2?:>2=D H:E9 :?E24E :>>F?6 DJDE6>D] &D:?8 E96 xsx?':G@ A=2E7@C>[ sCF8 u2C> 92D :56?E:7:65 ?@G6= :??2E6 :>>F?:EJ A2E9H2JD 2?5 E2C86ED 2?5 :D ?@H C2A:5=J 25G2?4:?8 >F=E:A=6 7:CDE\:?\4=2DD 5CF8 42?5:52E6D :?E@ 4=:?:42= 56G6=@A>6?E] u@C >@C6 :?7@C>2E:@? A=62D6 G:D:Ei k2 9C67lQ9EEADi^^4ED]3FD:?6DDH:C6]4@>^4E^r%n:5lD>2CE=:?<U2>AjFC=l9EEADTbpTauTauHHH]5CF8\72C>]4@>U2>Aj6D966Eldc'ehfecU2>Aj?6HD:E6>:5la_ac'a'hdfc'g'U2>Aj=2?l6?\&$U2>Aj2?49@Cl9EEADTbpTauTauHHH]5CF8\72C>]4@>U2>Aj:?56IlbU2>Aj>5dlh2h3e6a2dh4_a'2g7dd'ae6dbcbdeg64Q C6=lQ?@7@==@HQ D92A6lQC64EQm9EEADi^^HHH]5CF8\72C>]4@>k^2m]k^AmkAm':6H D@FC46 G6CD:@? @? k2 9C67lQ9EEAi^^3FD:?6DDH:C6]4@>Qm3FD:?6DDH:C6]4@>k^2mik2 9C67lQ9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'hdfc'g'^6?^Q C6=lQ?@7@==@HQm9EEADi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'hdfc'g'^6?^k^2mk^AmkAmr~}%pr%i &?:E65 $E2E6Dik^Am kAmw6?C: {:496?DE6:?[ !9]s]k^AmkAmr9:67 tI64FE:G6 ~77:46Ck^AmkAmt>2:=i9=:496?Do5CF8\72C>]4@>k^AmkAmr9:?2ik^AmkAm%@?J )F[ !9]s]k^AmkAmr@\7@F?56C 2?5 r9:67 ~A6C2E:?8 ~77:46Ck^AmkAmt>2:=iE@?J]IFo5CF872C>:?4]4@>k^AmkAmzt*(~#si r~}}tr%xr&% |p#*{p}s &}x%ts $%p%t$ }~#%w p|t#xrpk^AmkAmx}s&$%#* zt*(~#si #t$tp#rw x}utr%x~&$ sx$tp$t$ vt}t%xr$ r{x}xrp{ %#xp{$ rp#sx~{~v* qx~%trw}~{~v* !wp#|prt&%xrp{ wtp{%w ~!%xrp{ $rxt}rtk^AmkAm$~&#rti sCF8 u2C>k^AmkAmr@AJC:89E qFD:?6DD (:C6 a_ac]k^AmkAm!&qi 'a^'h^a_ac _cibh !|^sx$ri 'a^'h^a_ac _cibh !|k^AmkAmk2 9C67lQ9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'hdfc'g'^6?Qm9EEAi^^HHH]3FD:?6DDH:C6]4@>^?6HD^9@>6^a_ac'a'hdfc'g'^6?k^2mk^Am